论文部分内容阅读
目的观察氟尿嘧啶缓释颗粒瘤床植入对食管癌根治术后局部复发的疗效和预后影响。方法纳入2009年1~12月期间重庆三峡中心医院60例行食管癌根治术患者,按其治疗方法分为试验组和对照组两组,每组30例。试验组男24例、女6例,年龄(62.00±7.70)岁;对照组男23例、女7例,年龄(60.20±8.20)岁。试验组患者术中在瘤床植入氟尿嘧啶缓释颗粒300 mg,对照组不植入任何物质。比较两组患者临床结果差异。结果两组患者术后主要并发症发生率差异无统计学意义(P>0.05),试验组术后复发时间较对照组显著延长(P<0.05)、试验组术后复发病灶大小及复发病灶的个数较对照组显著减少(P<0.05);两组患者1年生存率差异无统计学意义,但试验组患者2年及3年生存率显著高于对照组(P<0.05),试验组中位生存时间较对照组显著延长[(29.2±1.9)月vs.(23.4±1.4)月,P<0.05]。结论食管癌术中瘤床植入氟尿嘧啶缓释颗粒能延缓肿瘤复发时间、提高食管癌患者2年及3年生存率,延长患者中位生存时间,而不增加术后并发症的发生,是一种安全、有效的局部化疗方法。
Objective To observe the effect and prognosis of local recurrence of esophageal carcinoma after radical implantation of fluorouracil. Methods Sixty patients undergoing esophageal cancer radical mastectomy in Chongqing Three Gorges Central Hospital from January to December in 2009 were divided into two groups according to their treatment: experimental group and control group, with 30 cases in each group. There were 24 males and 6 females in the experimental group, with a mean age of (62.00 ± 7.70) years. The control group consisted of 23 males and 7 females, with a mean age of (60.20 ± 8.20) years. In the test group, intraoperative implantation of fluorouracil sustained-release granules 300 mg in the tumor bed, the control group did not implant any substance. The differences in clinical outcomes between the two groups were compared. Results There was no significant difference in the incidence of major complications between the two groups (P> 0.05). The recurrence time of the experimental group was significantly longer than that of the control group (P <0.05). The size of the recurrent lesions and recurrent lesions (P <0.05). There was no significant difference in one-year survival rate between the two groups, but the 2-year and 3-year survival rates in the experimental group were significantly higher than those in the control group (P <0.05) The median survival time was significantly longer than that in the control group [(29.2 ± 1.9) months vs. (23.4 ± 1.4) months, P <0.05]. Conclusion Intraoperative implantation of fluorouracil sustained-release granules in esophageal carcinoma tumor bed can delay the time of tumor recurrence, improve the 2-year and 3-year survival rates of patients with esophageal cancer and prolong the median survival time without increasing the incidence of postoperative complications A safe and effective local chemotherapy.